Background: Combination antiretroviral therapy (ART) suppresses HIV-1 replication, but does not restore CD4 þ T-cell counts in all individuals. To investigate the effects of maraviroc on HIV-1 persistence and the relations between virologic and immunologic parameters in individuals with incomplete CD4 þ T-cell recovery, we performed a prospective, open-label pilot trial in which maraviroc was added to a suppressive ART regimen for 24 weeks.
Introduction
Antiretroviral therapy (ART) for HIV-1 infection rapidly suppresses plasma viremia to levels undetectable by clinical assays (HIV-1 RNA <50 copies/ml) [1, 2] . In the majority of individuals, suppressing viral replication with ART correspondingly increases CD4 þ T-cell counts [3] [4] [5] . However, in a subset of individuals known as immunological nonresponders, CD4 þ T-cell levels do not recover, leaving these individuals at a greater risk of opportunistic infections and mortality [6] [7] [8] [9] [10] [11] . A metaanalysis of 46 treatment groups from 17 phase 2-3 clinical studies showed that CCR5 antagonists increased CD4 þ T-cell counts more than comparator regimens independently of viral suppression [12] , suggesting that maraviroc may improve CD4 þ T-cell counts in immunologic nonresponders to ART.
We previously reported, however, that maraviroc intensification for 24 weeks in AIDS Clinical Trials Group (ACTG) study A5256 did not increase in CD4 þ T-cell counts in the periphery, but did lower levels of immune activation and apoptosis in both the CD4 þ and CD8 þ T-cell compartments [13] . Other studies with maraviroc have observed trends towards decreased immune activation in CD4 þ T-cells [14] , CD8 þ T-cells [15] or CD4 þ and CD8 þ T-cells [16] . In HIV-1 uninfected patients receiving haematopoietic stem cell transplantations for cancer, maraviroc limited visceral graft versus host disease, suggesting that blockade of CCR5 can inhibit lymphocyte trafficking [17] . However, a placebo controlled study by Hunt et al. [18] found increased levels of HLA-DR þ CD8 þ T-cells in the periphery and increased levels of HLA-DR þ CD4 þ and CD8 þ T-cells in rectal tissue during maraviroc intensification. Interestingly, changes in low-level plasma viremia were not observed despite the changes in immune activation. In addition, a study by Gutiérrez et al. [16] also found a transient increase in 2-long terminal repeat (2-LTR) circles despite a decrease in immune activation, although this effect was not observed in a different study [15] .
These divergent findings indicate that the impact of maraviroc intensification on immune activation and residual plasma viremia, and the relationships between measures of viral persistence and immune activation and apoptosis in the context of maraviroc intensification remain incompletely understood. To more thoroughly evaluate the impact of maraviroc intensification on virologic and immunologic parameters in individuals with stable but suboptimal CD4 þ T-cell recoveries on suppressive ART, we longitudinally measured residual plasma viremia, total and 2-LTR HIV-1 DNA in peripheral blood mononuclear cell (PBMC) and levels of immune activation and apoptosis in CD4 þ and CD8 þ T-cells in patients receiving maraviroc in ACTG study A5256. We also evaluated relationships between these parameters to gain further insight into the impact of maraviroc intensification.
Materials and methods

Study design and patient enrolment
The study design and patient enrolment for ACTG A5256 have been previously reported [13] . Briefly, A5256 was a prospective, multicentre, 48-week, singlearm, open-label trial in which HIV-1 infected individuals with plasma viremia (HIV-1 RNA) suppressed on ART and suboptimal CD4 þ T-cell recovery (defined as <250 cells/ml and a slope of annual change in the CD4 þ T-cell count from À20 to þ20 cells/ml during the past year) intensified their ART regimen by adding maraviroc (Pfizer Inc., New York, New York, USA) for 24 weeks; maraviroc was then stopped and preintensification ART was continued for an additional 24 weeks. Individuals had two assessments prior to maraviroc intensification (preentry and week 0) and then provided samples at 4, 8, 12, 16, 22 and 24 weeks after maraviroc intensification, followed by sampling at 12, 22 and 24 weeks after maraviroc discontinuation (study weeks 36, 46, and 48). Plasma HIV-1 RNA was quantified by a U.S. Food and Drug Administration (FDA)-approved assay at each visit to confirm viral suppression. The primary endpoint in A5256 was the change in CD4 þ T-cell counts from the average of two premaraviroc measurements to the average of CD4 þ T-cell counts from week 22 and week 24 during maraviroc as well as ART.
Quantification of residual plasma viremia
Stored plasma samples from the two premaraviroc timepoints and study weeks 12, 22, 24 and 36 were used to assess residual plasma viremia using a previously described assay with single copy sensitivity (SCA) [19] . Briefly, plasma was thawed and an internal standard (replication-competent avian leukosis virus long terminal repeat with a splice adaptor, RCAS) was spiked into the plasma. Virions were then pelleted by centrifugation at 170 000 Â g for 30 min and nucleic acid was isolated and resuspended in 55 ml of 5 mmol/l Tris-HCl supplemented with 1 mmol/l DTT and 1000 units of recombinant RNasin. A two-step quantitative real-time PCR (qRT-PCR) assay was then used to quantify levels of HIV-1 RNA and the internal standard RCAS from the isolated nucleic acid, as described previously [19] . A control assay without reverse transcriptase was included with each extraction to confirm the absence of HIV-1 DNA. The limit of detection for the single copy assay (SCA) is based on the input volume of plasma. With a typical volume of 3.0 ml of plasma, the limit of detection is 0.6 copies/ml of plasma.
Quantification of total and 2-LTR circle HIV-1 DNA To quantify total and 2-LTR HIV-1 DNA, nucleic acid was isolated from cryopreserved PBMCs and qRT-PCR assays were performed as described previously [20] . Briefly, PBMCs were thawed and nucleic acid was isolated using the Qiagen FlexiGen kit for total HIV-1 DNA and the Q1Aprep Spin Miniprep Kit for 2-LTR circles [21, 22] (Qiagen, Venlo, Limburg, the Netherlands). Separate qPCR assays using previously established primers and probes for total HIV-1 DNA [23] and 2-LTR circles [20] were used to evaluate cellular levels of HIV-1 DNA. A total of 12.5 ml of nucleic acid extract (equivalent to 6.25 Â 10 5 PBMC, as determined by Quant-iT PicoGreen dsDNA kit [24] ) was added to 37.5 ml of TaqMan Platinum Quantitative PCR Super Mix-UDG with Rox qRT-PCR cocktail for each assay [20] (Life Technologies, Carlsbad, California, USA). Levels of total and 2-LTR HIV-1 DNA in this study were evaluated at two premaraviroc time points, and week 12 and week 24 postmaraviroc. All qRT-PCR was performed using the Applied Biosystems 7900 Realtime PCR (Life Technologies) platform with appropriate positive and negative controls. Total HIV-1 DNA values below the limit of quantification were imputed to a value of 10 copies/10 6 PBMC. Samples with HIV-1 DNA below the limit of detection were infrequent (four samples at study preentry, one at entry, two at week 12 and one at week 24, from a total of five unique donors).
To determine the amount of HIV-1 DNA or 2-LTR circles per 10 6 CD4 þ T-cells, the levels of HIV-1 DNA per 10 6 PBMC were normalized using the percentage CD4 þ T-cells from that timepoint.
Immunological assessments
Levels of immune activation and apoptosis within the T-cell compartment were assessed at the two premaraviroc timepoints and weeks 12, 22, 24, 36, 46 and 48 as previously reported [13] . Peripheral blood samples were collected in heparinized vacutainer tubes and shipped overnight to a central processing laboratory wherein PBMC were isolated by density gradient centrifugation and immunologic measurements were performed. CD4 þ and CD8 þ T-cell activation was evaluated by measuring the frequency of either CD3 þ CD4 þ or CD3 þ CD8 þ cells that were CD38 þ HLA-DR þ . Cells were fixed in 2% formaldehyde and evaluated within 24 h. The frequency of CD4 þ and CD8 þ T-cells that were negative for the intracellular marker Bcl-2 or positive for caspase-3 were quantified by performing surface staining and then fixing and permeabilizing the cells to evaluate the extent of apoptosis within the T-cell compartment. All cells were analysed on an LSR II Flow Cytometer (Becton Dickinson, Franklin Lakes, New Jersey, USA) using FACS Diva software, v.6.1.1. Analysis of flow data was performed using FlowJo software, v.8.8.6 (Tree Star Inc., San Carlos, California, USA).
Statistical analysis
Change in residual viremia (<1 copy/ml/!1 copy/ml) and 2-LTR circles (positive/negative) over 24 weeks of maraviroc intensification were assessed with an exact McNemar's test. In the event of repeated measures at a given timepoint (e.g. two pre and two postmaraviroc timepoints for residual viremia), detectability was defined on the basis of detection at either timepoint. The median change in total HIV-1 DNA (log 10 copies/10 6 CD4 þ T-cells) and accompanying exact Hahn and Meeker 90% confidence interval (CI) were estimated, wherein the two premaraviroc values were averaged. Only individuals with results available for both premaraviroc and the week 24 timepoint on maraviroc were included. Associations between total HIV-1 DNA and markers of CD4 þ and CD8 þ T-cell immune activation and apoptosis were evaluated using Spearman's rank correlations. Relationships between premaraviroc covariates or change after maraviroc intensification and premaraviroc 2-LTR circles and SCA results were evaluated with exact Wilcoxon rank-sum test or Kruskal-Wallis test where appropriate.
Results
Study population
A total of 34 individuals were enrolled in A5256. Baseline characteristics of this study population have been described previously [13] . Of the 34 individuals, 32 were male (94%). Study participants had a median age of 50 (interquartile range: 47-55) years and a median duration of HIV-1 RNA suppression of 3 years (Q1-Q3: 1.8-4.5). The median CD4 þ T-cell count at baseline was 153 (Q1-Q3: 119-203) cells/ml, and the median CD8 þ T-cell count at baseline was 559 (Q1-Q3: 416-872) cells/ml. Longitudinal plasma HIV-1 RNA testing with an FDA-approved assay showed that two individuals (6%) experienced virologic failure (two consecutive measurements of HIV-1 RNA levels at or above the limit of detection of the assay used) during maraviroc intensification and discontinued maraviroc. These two individuals were excluded from further analysis, as well as one individual with a viral rebound at week 24. Table 1 and Figure 1 show residual viremia as measured by SCA during maraviroc intensification through 12 weeks There was no apparent difference in the probability of detectable residual viremia between premaraviroc timepoints and week 22/24 after maraviroc intensification (P ¼ 1.0); 74% of individuals had concordant outcomes (i.e. had detectable residual viremia at both premaraviroc and week 22/24 or had no detectable virus at both timepoints). Among individuals with detectable residual viremia, median levels of residual viremia were 2.9 and 2.4 copies/ml of plasma premaraviroc versus 4.9 and 3.9 copies/ml after 22 and 24 weeks of maraviroc dosing. Twelve weeks after stopping maraviroc, 43% of individuals had detectable viremia, with a median level of 4.3 copies/ml of plasma. When comparing week 22/24 versus week 36, no difference in the probability of detectable residual viremia was found (67% of individuals with concordant outcomes, P ¼ 0.75).
Effect of maraviroc on residual plasma viremia
Effect of maraviroc on total and 2-LTR circle HIV-1 DNA
The median HIV-1 DNA level at premaraviroc was 4.3 (Q1-Q3: 4.0-4.6) log 10 copies per 10 6 CD4 þ cells, compared with 4.3 (Q1-Q3: 4.1-4.7) and 4.4 (Q1-Q3: 3.8-4.8) log 10 copies per 10 6 CD4 þ cells after 12 and 24 weeks of maraviroc intensification, respectively ( Table 2 ). The median change in total HIV-1 DNA from premaraviroc to week 24 was þ0.2 log 10 copies of HIV-1 DNA per 10 6 CD4 cells (90% CI -0.1 to þ0.3). . Impact of maraviroc intensification on low-level plasma viremia. Levels of plasma viremia were quantified by the single copy assay (SCA) at preentry, at maraviroc intensification (week 0) and 12, 22 and 24 weeks of maraviroc intensification and 12 weeks after maraviroc discontinuation. The limit of detection was 1 copy/ml (gray dashed line).
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2-LTR circles
were not detected in 82% of individuals during 24 weeks of maraviroc intensification; 14% of individuals had detectable 2-LTR circles at either of the premaraviroc timepoints and 4% at week 24 (Table 3) .
Comparing premaraviroc with week 24, there was no evidence of a difference in the probability of detectable 2-LTR circles (P ¼ 0.25); 89% of individuals had concordant outcomes (i.e. detectable 2-LTR circles at both premaraviroc and week 24 or had no detectable 2-LTR circles at both timepoints).
Relationships between virologic and immunologic parameters
A strong inverse correlation was found between premaraviroc levels of total HIV-1 DNA and premaraviroc levels of cellular immune activation in CD4 þ T-cells as measured by the percentage of CD38 þ HLA-DR þ (Fig. 2a ; rho ¼ À0.52, P ¼ 0.004). The relationship between total HIV-1 DNA and immune activation in CD4 þ T-cells was qualitatively similar but not statistically significant at week 24 following maraviroc treatment (rho ¼ À0.34, P ¼ 0.07). Conversely, there was no relationship found between levels of cellular activation on CD8 þ T-cells and total HIV-1 DNA levels ( Fig. 2b ; rho ¼ À0.14, P ¼ 0.482).
There was evidence of an inverse correlation between levels of apoptotic CD4 þ T-cells (percentage of Bcl-2-) and the level of HIV-1 DNA (Fig. 2c , rho ¼ À0. 36 , P ¼ 0.057); however, this association was not seen for percentage of caspase3 þ CD4 þ T-cells (data not shown), or between premaraviroc levels of apoptotic CD8 þ T-cells and HIV-1 DNA levels.
Following the addition of maraviroc for 24 weeks, the levels of cellular activation, as measured by CD38 þ HLA-DR þ , decreased 1.3% (90% CI À1.8 to À0.3) on CD4 þ T-cells and decreased 1.4% (90% CI À3.0 to À0.3) on CD8 þ T-cells [13] . The change in %CD38 þ HLA-DR þ CD4 þ cells was positively correlated with premaraviroc levels of total HIV-1 DNA (Supplemental Figure 1a ; http://links.lww.com/QAD/A753; rho ¼ 0.44, P ¼ 0.018), reflecting that individuals with the lowest premaraviroc HIV-1 DNA levels had the highest premaraviroc CD4 þ immune activation and largest decreases following maraviroc intensification. An association between changes in %CD38 þ HLA-DR þ CD8 þ cells and premaraviroc levels of total HIV-1 DNA was not apparent (Supplemental Figure 1b , http://links.lww.com/QAD/A753; rho ¼ 0.23, P ¼ 0.240). In addition, no association was seen between premaraviroc covariates (i.e. age, CD4 þ , CD8 þ , immune activation) or change after maraviroc intensification and premaraviroc detectability of residual viremia or detectability of 2-LTR circles (data not shown).
Discussion
In this study, we evaluated the impact of maraviroc ART intensification in patients with suboptimal CD4 þ T-cell recovery despite suppressive ART. We did not observe an effect of maraviroc intensification on the levels of residual viremia in our small cohort of patients, which is Effects of maraviroc on HIV persistence Cillo et al. 2125 consistent with the results of previous ART intensification studies with antiretrovirals from other drug classes, including protease inhibitors, nonnucleoside RT inhibitors and integrase inhibitors [18, [25] [26] [27] [28] . A study by Madrid-Elena et al. [29] also found no change in residual viremia following maraviroc administration, but did show that maraviroc upregulated NF-kB signalling in vivo and increased levels of cellular HIV-1 RNA, suggesting that maraviroc may have at least partial agonist activity despite being regarded as a CCR5 antagonist [30] . However, these findings are in contrast to a recent report demonstrating that maraviroc intensification does not affect gene expression in CD4 þ T-cells [31] .
There was no observed change in total or 2-LTR HIV-1 DNA in PBMC following maraviroc intensification. Unchanged levels of HIV-1 DNA are consistent with stability of HIV-1 DNA in individuals on long-term ART [32] . With regard to 2-LTR circles, Gutiérrez et al. [16] reported a statistically significant increase in 2-LTR circle detection after 12 and 24 weeks of maraviroc intensification in nine individuals on suppressive ART. The authors proposed that the increase in 2-LTR circle detection may be the result of a partial CCR5 agonist activity of maraviroc or from increased availability of cytokines following CCR5 blockade, leading to greater virus production and replication. In our study, 2-LTR detection was rare and did not appear related to maraviroc intensification, arguing against increased virus production. Consistent with our findings, Lafeuillade et al. [15] rarely detected 2-LTRs and did not find an increase in 2-LTR circles during maraviroc intensification.
When evaluating relationships between virologic and immunologic measurements prior to maraviroc intensification, we found a strong inverse correlation between percentage of HLA-DR þ CD38 þ CD4 þ T-cells and levels of total HIV-1 DNA. This inverse correlation contrasts with the modest positive correlation between total HIV-1 DNA and immune activation reported by Hatano et al. (rho ¼ 0.16, P ¼ 0.057) [33] . The reason for this discrepancy is unknown, but differences in the patient groups studied (immunologic nonresponders in the current study versus mostly immunologic responders in the other study [33] , see explanation below) and lack of standardized immunophenotyping assays between laboratories may have contributed. The overall higher level of immune activation in individuals with suboptimal CD4 þ T-cell recovery [34, 35] [36], and both immune activation and apoptosis are reduced following suppression of viral replication on ART [37] . In the current study, we found evidence to suggest greater premaraviroc CD4 þ T-cell apoptosis (Bcl-2 À ) in individuals with lower premaraviroc levels of HIV-1 DNA (and correspondingly higher levels of CD4 þ T-cell activation). The increased apoptosis observed may be driven by persistently higher levels of immune activation in immunologic nonresponders [35] , leading to greater cell death and lower HIV-1 DNA levels.
The accelerated death of HIV-1 infected cells is likely to be accentuated by the characteristically high levels of T-cell turnover and failure of homeostatic proliferation present in immunological nonresponders [34, 38] . The blockade of ongoing viral replication with stable, suppressive ART would prevent the generation of new HIV-1 infected cells, resulting in the lower HIV-1 DNA levels observed among individuals with higher T-cell activation and turnover.
We also found that lower premaraviroc levels of HIV-1 DNA were associated with higher levels of premaraviroc CD4 þ T-cell immune activation and greater reductions in CD4 þ T-cell immune activation following maraviroc intensification. As noted previously [13] , we did not observe increases in CD38 þ HLA-DR þ T-cells following maraviroc intensification as reported by Hunt et al. [18] . The explanation for these conflicting results remains elusive, but may have been caused by differences in sample processing between the studies, as discussed previously [13] . Other studies investigating the impact of maraviroc on immune activation have generally observed trends towards reduced CD4 þ CD38 þ T-cells [14, 39, 40] or no change in T-cell activation phenotype [30] . A decrease in CD4 þ T-cell activation following maraviroc intensification in those with higher levels of baseline activation could result from blockade of CCR5-mediated trafficking to effector sites (e.g. lymph nodes, gut mucosa), wherein T-cells would encounter cognate antigens and become activated. Preventing the interaction of CD4 þ cells with antigen-presenting cells could lead to lower levels of CD4 þ T-cell activation in the periphery, though this hypothesis requires further study.
In conclusion, our results are consistent with full suppression of viral replication with standard ART in that maraviroc did not have an effect on low-level viremia, 2-LTR HIV-1 DNA or the number of HIV-1 infected cells. Although maraviroc has an established role in the prevention of graft versus host disease by preventing the trafficking of T-cells to visceral sites [17] , its effects on T-cell activation in the context of HIV-1 infection are still unclear. Overall, the effects of maraviroc on T-cell activation in well controlled HIV-1 infection appear to be modest and variable across studies [13] [14] [15] 18, 31, 39, 40] , indicating limited potential for reducing chronic immune activation.
